Physician profile
Erica M Szabados
NPI 1346467560
$8,983.43
in general payments reported to CMS, 2019-2025
41 companies · $1,865 in 2025
The $1,865 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $946 · 2021: $2,188 · 2022: $1,657 · 2023: $1,001 · 2024: $663 · 2025: $1,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,528.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $984.45 | 2021-2025 | Ubrelvy, Qulipta, Duopa |
| Sk Life Science, INC. | $801.43 | 2020-2025 | |
| Amgen INC. | $624.67 | 2019-2023 | Aimovig |
| Lilly USA, LLC | $461.99 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Pfizer INC. | $454.52 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $432.82 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $371.28 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $302.93 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $273.58 | 2019-2025 | Ongentys, Rytary |
| Merz Pharmaceuticals, LLC | $261.36 | 2025 | Xeomin |
| Ucb, INC. | $250.87 | 2019-2023 | Nayzilam |
| Biohaven Pharmaceutical Holding Company Ltd. | $248.87 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $248.76 | 2021 | |
| Acorda Therapeutics, INC | $246.36 | 2019-2022 | |
| Kyowa Kirin, INC. | $246.31 | 2019-2024 | Nourianz |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $238.49 | 2021-2025 | Valtoco |
| Biogen, INC. | $238.34 | 2021-2025 | Skyclarys |
| Ge Healthcare | $235.16 | 2019-2025 | |
| Argenx US, INC. | $206.74 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $195.38 | 2019-2023 | |
| Allergan, INC. | $154.77 | 2020 | |
| Mdd US Operations, LLC | $147.93 | 2019-2025 | Gocovri, Gocovri |
| Lundbeck LLC | $146.47 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $138.08 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $136.83 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $128.86 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $124.36 | 2025 | Rexulti |
| Upsher-Smith Laboratories LLC | $98.21 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $80.24 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $77.43 | 2019-2023 | Ongentys, Ingrezza |
| Almatica Pharma LLC | $59.13 | 2021 | |
| Avion Pharmaceuticals | $56.70 | 2022-2023 | Dhivy |
| Impel Pharmaceuticals INC. | $53.43 | 2023 | Trudhesa |
| Scilex Pharmaceuticals INC. | $49.83 | 2024 | |
| Sumitomo Pharma America, INC. | $48.02 | 2023 | Aptiom |
| Promius Pharma LLC | $34.46 | 2019 | |
| Tanabe Pharma America, INC. | $34.42 | 2021-2022 | |
| Noctrix Health, INC. | $33.81 | 2025 | Nidra |
| Csl Behring | $28.54 | 2019 | |
| Akcea Therapeutics, INC. | $15.13 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Szabados listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.